RT Journal Article SR Electronic T1 Resistance to antibiotics in clinical isolates of Escherichia coli producing and non-producing Extended Spectrum Betalactamases (ESBL) obtained from urine cultures in patients with urinary tract infection JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2023.04.05.23288193 DO 10.1101/2023.04.05.23288193 A1 Benítez Vergara, María Guadalupe A1 Cruz Rosas, María Fernanda A1 Rojas García, Pablo Gustavo A1 García Contreras, Rodolfo A1 Martínez Gonzalez, Gabriel A1 Almeida Villegas, Jorge Angel YR 2023 UL http://medrxiv.org/content/early/2023/04/11/2023.04.05.23288193.abstract AB Objective Identify resistance patterns against various antibiotics in Escherichia coli producers and non-producers of extended spectrum beta-lactamases in urinary infections in a population of the Toluca Valley, MexicoIntroduction Escherichia coli is a bacterium that is part of the normal biota of the human being, but under certain conditions it can produce diseases such as gastrointestinal and urinary tract infections for which is the main responsible. Enterobacteriaceae such as Escherichia are extended spectrum betalactamases (ESBL) producers, which makes their treatment difficult due to a high rate of resistance to antibiotics.Methods 155 samples were collected from patients with suspected urinary tract infection without exclusion criteria such as age or gender. Automated equipment was used for the identification of the etiological agent and sensitivity tests. For the determination of ESBL, the double disc technique was used.Results 35 strains of Escherichia coli were obtained, of which 45.72 % have ESBL, these strains show 100 % resistance to betalactams, as well as high resistance to quinolones and tetracycline ranging from 70 to 100 %. On the other hand, the resistance shown by non-ESBL producing strains is variable both for betalactams and for other antibiotics.Conclusion Treatment for urinary tract infections has become increasily difficult due to the high rate of resistance to antibiotics, mainly ESBL-producing strains such as the E coli strains in the present study. Where high rates of resistance to different antibiotics used in clinical practice are shown.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received to carry out this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The following study was approved by the ethical committee of the research division of the Faculty of Medicine UNAM.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesYes